<DOC>
	<DOCNO>NCT00754312</DOCNO>
	<brief_summary>The primary objective study evaluate change expression target biomarkers invasive breast cancer tissue SNDX-275 administration .</brief_summary>
	<brief_title>A Phase I , Multicenter , Open Label Study Effects SNDX-275 Expression Biomarkers Subjects With Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Inclusion criterion : Is schedule breast biopsy due suspicious mass palpable ≥1 cm mammogram Must able receive two dos study medication 7 day apart prior surgery Has histologically confirm invasive breast cancer ER positive , ER and/or PR negative histology triple negative ( ER , PR , HER2 ) histology Has ECOG performance status ≤ 2 Has clinically significant laboratory cardiac abnormality Has negative serum pregnancy test Screening either post menopausal , sterile willing use approve method contraception . Is able swallow retain oral medication Exclusion criterion : Has concomitant medical condition precludes adequate study treatment compliance assessment , : . Bleeding disorder would increase risk additional core biopsy biomarkers b . Morbid obesity Is currently receive treatment medication prohibit medication list Has allergy benzamides inactive component study drug Is participate another clinical trial receive another investigational agent within 30 day prior inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>breast cancer</keyword>
</DOC>